Delving into the Latest Updates on Cinnarizine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine, 1-Benzhydryl-4-cinnamylpiperazin, 1-Cinnamyl-4-(diphenylmethyl)piperazine

+ [11]

Target

H1 receptor

Action

antagonists

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesOtorhinolaryngologic Diseases+ [1]

Active Indication

Cerebrovascular DisordersVertigo

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC26H28N2

InChIKeyDERZBLKQOCDDDZ-UHFFFAOYSA-N

CAS Registry298-57-7

The goal of this pilot, open-label prospective study is to evaluate if the effect of calcium channel blockade on plasma aldosterone levels in people with primary aldosteronism (PA) is due primarily to Cav1.3 blockade.
This will be tested by treating participants who have PA with both cinnarizine (Cav1.3 blocker) and nifedipine (Cav1.2 blocker) and evaluating effect on aldosterone levels and blood pressure over a two week course of treatment.

Start Date24 Apr 2023

Sponsor / Collaborator

Queen Mary University of London

IRCT20221108056444N1

/ RecruitingPhase 3IIT

Comparison of the effectiveness of Cinnarizine V/S Topiramate in migraine prophylaxis of children referred to pediatric neurology clinic

Start Date23 Sep 2022

Sponsor / Collaborator-

IRCT20110628006907N16

/ SuspendedPhase 3IIT

Interventional comparison of the effect of cinnarizine with placebo on mood swings and self-harm and stereotyped behaviors of autistic patients

Start Date20 Jan 2022

Sponsor / Collaborator

Tehran University of Medical Sciences

100 Clinical Results associated with Cinnarizine

Login to view more data

100 Translational Medicine associated with Cinnarizine

Login to view more data

100 Patents (Medical) associated with Cinnarizine

Login to view more data

1,720

Literatures (Medical) associated with Cinnarizine

14 Apr 2025·Journal of Chemical Information and Modeling

Application of Deep Learning to Predict the Persistence, Bioaccumulation, and Toxicity of Pharmaceuticals

Article

Author: Roberti, Marinella ; Evangelista, Dominga ; Bolognesi, Maria Laura ; Bernetti, Mattia ; Nelson, Elliot ; Skyner, Rachael ; Tehan, Ben ; Bottegoni, Giovanni

This study investigates the application of a deep learning (DL) model, specifically a message-passing neural network (MPNN) implemented through Chemprop, to predict the persistence, bioaccumulation, and toxicity (PBT) characteristics of compounds, with a focus on pharmaceuticals. We employed a clustering strategy to provide a fair assessment of the model performances. By applying the generated model to a set of pharmaceutically relevant molecules, we aim to highlight potential PBT chemicals and extract PBT-relevant substructures. These substructures can serve as structural flags, alerting drug designers to potential environmental issues from the earliest stages of the drug discovery process. Incorporating these findings into pharmaceutical development workflows is expected to drive significant advancements in creating more environmentally friendly drug candidates while preserving their therapeutic efficacy.

03 Mar 2025·Angewandte Chemie International Edition

Hydroalkylation of Vinylarenes by Transition‐Metal‐Free In Situ Generation of Benzylic Nucleophiles Using Tetramethyldisiloxane and Potassium tert‐Butoxide

Article

Author: Nugraha, Hana ; Newman, Stephen G. ; Onge, Piers St.

AbstractHydrosilanes and Lewis bases are known to promote various reductive defunctionalizations, rearrangements, and silylation reactions, facilitated by enigmatic silicon/Lewis base‐derived reactive intermediates. Despite the wide variety of transformations enabled by this reagent combination, no examples of intermolecular C(sp3)−C(sp3) forming reactions have been reported. In this work, we've identified 1,1,3,3‐tetramethyldisiloxane (TMDSO) and KOtBu as a unique reagent combination capable of generating benzylic nucleophiles in situ from styrene derivatives, which can subsequently react with alkyl halides to give a new C(sp3)−C(sp3) linkage via formal hydroalkylation. Mechanistic experiments suggest that the reaction proceeds through a key hydrogen atom transfer (HAT) step from a hydrosilane reducing agent to styrene, affording a benzylic radical that undergoes reductive radical polar crossover (RRPC) and subsequent SN2 alkylation.

01 Mar 2025·Annals of Pharmacotherapy

Outcome of Drug-Induced Parkinsonism in the Elderly: A Permanent Nonprogressive Parkinsonian Syndrome May Occur Following Discontinuation of Cinnarizine and Flunarizine

Article

Author: Calzetti, Stefano ; Negrotti, Anna

Parkinsonism induced by dopamine receptor antagonists, traditionally considered completely reversible following offending drug withdrawal, may unmask a degenerative parkinsonism in the patients with an underlying subclinical disease. In elderly patients, parkinsonism induced by the calcium channel blockers such as piperazine derivates cinnarizine and flunarizine may persist following drug discontinuation resulting in a permanent nonprogressive syndrome fulfilling the criteria for tardive parkinsonism. Whether this outcome occurs also following exposure to dopamine receptor antagonists such as neuroleptics and benzamide derivates or represents a class effect of the voltage-gated L-type calcium channel blockers, such as cinnarizine and flunarizine, due to their complex pharmacodynamic properties remains to be established.

100 Deals associated with Cinnarizine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01295	Cinnarizine	N07CA02	DB00568

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cerebrovascular Disorders	-	-	-
Vertigo	-	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ENDO2024	Not Applicable	Hypoaldosteronism CACNA1D mutations	15	Cinnarizine 30 mg	(jvfnpdcpms) = tiryfxjjer blzdevuamy (zvdygsoqlj, 1268 - 3764)	Negative	01 Jun 2024
				Nifedipine 60 mg	(jvfnpdcpms) = wjnajzqslp blzdevuamy (zvdygsoqlj, 825 - 2946)